Enacted on December 28, 2022

1. General information

KD is the official journal of the KSKD, published biannually. The journal is operated according to the Principles of Transparency and Best Practice in Scholarly Publishing 4th ed (https://publicationethics.org/resources/guidelines-new/principles-transparency-and-best-practice-scholarly-publishing). There are no specific limits to contribution requirements, but the scope of content should be in accord with the "aims and scope" of the journal. KD solicits competent investigators’ contributions including original articles, reviews, editorials, case reports and special contributions. Authors should refer to the "Information for contributors" of the journal, the Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals by the ICMJE (https://www.icmje.org/recommendations/), and Good Publication Practice Guidelines for Medical Journals (KAMJE, https://www.kamje.or.kr/board/view?b_name=bo_publication&bo_id=13&per_page=).

2. Editorial policy

The editorial board presumes that all authors listed in a manuscript have agreed to the following policy of KD on submission of the manuscript.

Any authors may submit manuscripts of original articles, reviews, editorials, case reports, and special contributions written in Korean or English. Except for negotiated secondary publications, manuscripts submitted to the journal must be previously unpublished and not under consideration for publication elsewhere.

The editorial board reserves the right to make corrections, both literary and technical, to the papers. Under any circumstances, the identities of the reviewers will not be revealed. It is the author's responsibility to ensure that a patient's anonymity be carefully protected, to verify that any experimental investigation with human participants reported in the manuscript was performed with informed consent, and to follow all guidelines for experimental investigation with human participants required by the institution(s) with which all the authors are affiliated.

If an author should be added or deleted after the submission, it is the responsibility of the corresponding author to ensure that the author concerned are aware of and agree to the change in authorship. The editorial board has no responsibility for such changes.

KD is published biannually on the last day of June and December. All published articles become permanent properties of KSKD and they may not be published elsewhere without written permission.

3. Preparing manuscripts

A. Categories of manuscripts

KD publishes original article, review, editorial, case report, and special contribution.

Original article: Original investigations in areas relevant to Kawasaki Disease. Maximum 4,000 words, 6 tables or figures, and 35 references. Include a structured abstract and its length should not exceed 300 words. Additional material may be placed in appendices. Systematic reviews are critical assessments and evaluations of research (not simply summaries) that attempt to address a focused clinical question using methods designed to reduce the likelihood of bias. Meta-analyses combine this with aggregate analyses. This kind of manuscripts should be structured into the subheadings: introduction, main subject, and conclusion. Such articles must be compliant with relevant guidelines and include a narrative abstract and its length should not exceed 300 words. In case of systematic review, the length is limited to 5,000-8,000 words with a maximum of 100 references.

In case of Korean article, less than 8 pages of the printed journal are recommended for original article. (1 page of this journal contains about 2,500 Korean characters when only characters are included in the page).

Review: Clinical reviews should address specific clinical questions or relevant issues regarding Kawasaki disease. Such articles should summarize current research relevant to the questions they address, be evidence-based to the extent possible, be balanced, and detail the importance of the questions or issues. Include a narrative abstract and its length should not exceed 300 words. Do not combine a case report with your review. This kind of manuscript should be structured into subheadings: introduction, main subject, and conclusion. The length is limited to 5,000 words. The number of figures, tables, or references are not limited.

Editorials: It is written upon the request of the editorial board. It covers authoritative comments or opinions on controversial matters with significant implications for Kawasaki disease; or, qualified, thorough analysis and criticism of KD articles. Maximum 1,500 words.

Case report: Case report must be a brief description of a previously undocumented disease process, a unique manifestation or treatment of a known disease process or unreported complications of treatment regimens. Entities previously reported elsewhere must be extremely important to be considered. Include a narrative abstract with keywords, introduction, case, discussion focusing on the implications of the case reported, references, and figures or tables. Maximum 1,500 words, 20 references, and 4 tables or figures. The abstracts should not exceed 250 words.

Special contribution: This kind of manuscript does not conform to a traditional format. Please discuss with the editorial board before submission.

Authors should discuss with the editorial board if their article exceeds the maximum number of words, figures or tables allowed.

Table. Recommended maximums for articles submitted to the KD

B. Reporting guidelines for specific study designs

For the specific study design, such as randomized control studies, studies of diagnostic accuracy, meta-analyses, observational studies, and non-randomized studies, it is recommended that the authors follow the reporting guidelines listed in Table.

Table. Reporting guidelines

C. Registration of clinical trial research

Any research that deals with a clinical trial should be registered to the primary registry, such as the WHO International Clinical Trials Portal (https://www.who.int/clinical-trials-registry-platform), NIH ClinicalTrials.gov (https://www.clinicaltrials.gov/), ISRCTN Resister (https://www.isrctn.com/), and Clinical research information system (https://cris.nih.go.kr/cris/index.jsp). The clinical trial registration number should be published at the end of the abstract.

D. Preparing manuscripts

We accept manuscripts written in English or Korean. Even for Korean manuscripts, the title page should be written in both English and Korean, and the abstract with keywords, references, tables, figures, and figure legends must be written in English. Authors who are non-native speakers should receive English-editing service. All text files should be in Microsoft Word format (doc or docx, 2007 and above), and all figures need to be in JPG/JPEG/TIFF/PPT format. Files should not be uploaded as PDF. The manuscript should be typed in a 12-point font and double-spaced on A4 with a 2츠 margin on both sides and a 3cm margin on the top and bottom. Page numbers should start from 1, indicated at the bottom center of each page, beginning with the title page of the submitted manuscript. Line numbers should be displayed on the left side of the manuscript and should continue consecutively without starting anew on each page.

The manuscript should be organized in the following order: full title page (including all the authors’ details) as a separate file; blinded main document in a single file, which starts with abstract with keywords, introduction, methods, results, discussion, references, and figure legends. Tables and figures should be uploaded separately.

The use of abbreviations should be minimized. When used, they should be fully described at first appearance in the text and described in the parenthesis. Use of Korean terms need to be consistent with the latest version of lexicon published from Korean Medical Association (http://term.kma.org/index.asp). If Korean terms are unavailable (medical terms, proper nouns, place names, drug names or units), authors may use English terms. Even if Korean terms are poorly understandable, authors should use only Korean terms after describing the corresponding English terms in parentheses at first appearance. Leave blanks between English words and subsequent parentheses (c.f., no blanks between Korean words and parentheses).

Radiation measurements and laboratory values should be in accordance with the International System of Units (SI). However, some customarily used units (e.g., mmHg) are acceptable. Leave blanks in front of units except % and ℃. P values should be typed in capital letters ("P") and should be marked as "P value" in the table.

KD performs double-blinded review of the submitted manuscripts. The authors' names, affiliations, and any other remarks that may identify the authors should not appear in the main document, figures, and appendices for the blinded review. In case identifying details are found, the editorial board will ask the corresponding author to re-upload the files after deleting such details before referring peer review.

The names and locations (city or province/country or state) of the manufacturers of equipment and generic names should be given.

Please also refer to KD article templates and recent articles for style.

E. Title page

Include the following items on the full title page.

1. Type of manuscript (e.g., original article)

2. Title: Both English (≤50 words) and Korean (≤50 letters) titles are needed (English manuscripts do not need Korean titles).

3. Full names, affiliations, and order of all authors: Each author’s full name must be provided in the order of first name, middle name, and last name. Academic degree is not required. When authors from different institutions (name of academic institution is preferred) are included, the authors should be matched with their organizations by placing the relevant organization number in superscript after each author’s name.

e.g., Mi Young Han1

11Department of Pediatrics, College of Medicine, Kyung Hee University, Seoul, Korea

4. Information of the corresponding author (Name, affiliation, academic degree, ORCID, postal address, phone number, fax number, and e-mail address).

5. Running title: This title will be printed at the top of each page of the published paper and should be no longer than 10 words (including spaces). Even Korean manuscripts need English running titles.

6. ORICID, COI, and funding sources: All authors write their ORCID and clearly disclose their COI and funding sources. If not applicable, indicate so.

7. Author contributions: Specify each author's contribution to the article.

8. Acknowledgments (optional): Persons who have made substantial contribution, but who are not eligible as authors are named in the acknowledgments.

9. IRB number: IRB approval number should be typed (e.g., IRB no. ##-##-###).

10. words count: For English article, please provide the word count of the main text and figure legends, excluding the title page, abstract, tables, and references.

F. Main body

The main body is a blinded document for review and should contain the following components in a single file, which starts with abstract and keywords, introduction, methods, results, discussion, references, and figure legends. Tables and figures should not be embedded in the text.

Abstract

Abstracts for original articles should be 300 words or less, and structured into the subheadings: Background, Methods (include information on design, setting, participants, interventions, and main outcomes measured), Results, and Conclusion. But narrative abstracts are necessary in review, case reports. In your results, you should emphasize the magnitude of findings over test statistics, ideally including the size of the effect and its confidence intervals for the principal outcomes. Citations should not be used in the abstract. Abbreviations should be minimized and, if used, must be defined within the abstract by the full term followed by its abbreviation in parentheses. Keywords should be listed using 5-10 Medical Subject Headings (MeSH, https://meshb.nlm.nih.gov/search) joined by semicolons. In case of an RCT, the trial registry number should appear after the conclusion (e.g., NCT01616745).

Main body

1) Introduction

The most effective introduction section should concisely argue how the topic is new, scientifically important, and clinically relevant. Usually, we recommend three paragraphs: The first paragraph to describe the circumstances or historical context that led you to investigate the issue. The second to describe why your investigation is consequential. What are its potential implications? How does it relate to issues raised in the first paragraph? Why is this specific investigation the next logical step? The last to explain the goals of this investigation: Clearly state the specific research objective or hypothesis and your primary outcome measure.

2) Methods

• This section should include subsections with contents that detail the study design, study setting and population, study protocol, measurements or key outcome measures, and data analysis (include sample size determinations and other relevant information, the names of statistical tests, and software used).
• The role of funding organizations and sponsors in the conduct and reporting of the study should be included here.
• When equipment is used in a study, provide in parentheses the model number, name, and location of the manufacturer.
• If citing an in-press paper for the description of methods, please upload a copy of the in-press paper for the editor and reviewers. This in-press material will be handled with appropriate confidentiality.
• Research involving human participants or animals must meet local, legal and institutional requirements, and generally accepted ethical principles such as those set out in the Nuremberg Code, the Belmont Report, or the Declaration of Helsinki.
• Manuscripts reporting data involving human participants must indicate a positive review by an IRB or equivalent. This requirement includes studies that qualify for IRB expedited status. Most institutions require IRB review of studies that qualify for exempt status and that this determination be made by the IRB, not by the authors. The "Methods" section of the manuscript must explicitly state that IRB approval was obtained, that the IRB determined the study was exempt, or that the study did not involve human participants (e.g., publicly available and previously de-identified information from national data sets, or other studies not meeting the definition of human participants research, additional information available at www.hhs.gov/ohrp/policy/cdebiol.html). IRB approval number should be typed after this remark (e.g., IRB no. ##-##-###). The "Methods" section should also indicate the type of consent used (written, verbal, or waived), and confirm that consent was obtained from all participants (unless waived by the IRB).
• Manuscripts reporting the results of investigations of live vertebrate animals must indicate approval by an IACUC or equivalent. We reserve the right to request submission of IRB or IACUC documentation at any time.
• When working with administrative databases, authors should be diligent in checking the validity of variables (e.g., by cross-checking with other variables in the dataset) and patterns of missing data. Both of these factors can bias results. Authors should also recognize that causal inferences are generally limited when interpreting results from administrative data sources. For analyses using probability samples, care should be taken to use clusters, strata and weights in analyses and that substantially restricting such samples (e.g., to small age groups) may create bias and unusual associations between variables.

3) Results

This section should be concise, and include the statistical analysis. Results presented in tables or figures should be referred to in the text, but the material should not be presented again. In addition to the data collected in the study, the results should also indicate the success of protocol implementation (e.g., was blinding successful, was there a high inter-rater reliability?). In keeping with the recommendations of the Institute of Medicine regarding gender-specific research, ensure correct use of the terms sex (when reporting biological factors) and gender (identity, psychosocial or cultural factors). We ask that "all papers reporting the outcomes of clinical trials report on men and women separately unless a trial is of a sex-specific condition (such as endometrial or prostatic cancer)." (Women’s Health Research: Progress, Pitfalls, and Promise; National Academies Press 2010, available at https://www.tandfonline.com/doi/abs/10.1080/07399332.2011.562837). If the study was done involving an exclusive population, for example in only one sex, authors should justify the reasons, except in obvious cases.

4) Discussion

Briefly summarize the results and how they relate to your area of investigation. Consider only those published articles directly relevant to interpreting your results and placing them in context. Do not stress statistical significance over clinical importance. Do not use a separate conclusion section, but instead append it as the last paragraph of the Discussion beginning something like: "In summary . . ." Take care that the conclusion is restricted to what can be justified by your experimental results. Discuss shortcomings and biases related to study design and execution.

G. References

1) The list should be numbered consecutively in the order in which they are first mentioned in the text. Every reference must be cited at least once in the text. Each reference should be cited as Arabic numerials (Vancouver style). Although the number should be typed after author’s surname, it should be typed at the end of the sentence but ahead of the period, if no author’s surname is typed in there. If authors’ number is less than three, all the authors’ surname should be typed. However, in case of three or more authors, the superscript should be located after the first author’s surname.

2) The abbreviated journal title should be used according to the NLM catalog (https://www.ncbi.nlm.nih.gov/nlmcatalog/journals) or the KoreaMed (https://www.koreamed.org/).

3) If there are six or fewer authors in a reference, list all authors. If the number of authors is greater than six, list the initial six authors, and then abbreviate the rest of the authors with by "et al."

4) Personal communications and unpublished data should be cited in the body of the paper in parentheses, not listed in the references section. Manuscripts that have been accepted for publication may be listed as "Forthcoming"; manuscripts that have been submitted or are under revision but have not been accepted should not be cited as references.

5) The use of abstracts that have not been published as full manuscripts is discouraged.

6) Authors are responsible for the accuracy and completeness of the references and text citations.

7) Number of references is limited to 35 in original articles (but, 100 in systematic reviews), 20 in case reports, and unlimited in reviews. The style and punctuation for references should follow the format illustrated in the following examples. For types not addressed in these examples, the author is referred to the Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals by the ICMJE (https://www.icmje.org/recommendations/), and Good Publication Practice Guidelines for Medical Journals, 2nd ed (KAMJE, https://www.kamje.or.kr/board/view?b_name=bo_publication&bo_id=13&per_page=).

Journal article

1. Lee JY, Lee BH, Kim GH, Jung CW, Lee J, Choi JH, et al. Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups. Clin Exp Pediatr. 2012;55:48-53.

Book & Book chapter

2. Volpe JJ. Neurology of the newborn. 5th ed. Philadelphia, PA: Saunders; 2008.

3. Hong CE. Textbook of pediatrics. 9th ed. Seoul: Korea Textbook; 2008.

4. Pan ES, Cole FS, Weinttrub PS. Viral infections of the fetus and newborn. In: Taeusch HW, Ballard RA, Gleason CA, editors. Avery’s diseases of the newborn. 8th ed. Philadelphia, PA: Elsevier Saunders; 2005. p. 495-529.

Website

5. International Committee of Medical Journal Editor. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication [Internet]. Philadelphia, PA: International Committee of Medical Journal Editor; c2009 [cited 2012 Nov 1]. Available from: http://www.icmje.org/urm_main.html

Tables

Tables should be referenced in the main text in sequential order, and uploaded separately with the text. A descriptive title that is composed of a phrase without a period at the top of the table. Define all abbreviations in a footnote to the table. If necessary, footnote markers can be used as listed order using superscript letters such as 1), 2), 3)…etc. If a table has been previously published should be accompanied by the written consent of the copyright holder and the footnote must acknowledge the original source.

Figures and legends

Figures must be referenced in the text in sequential order as Fig.1, Fig.2, Fig.3, and so on. Figures should clarify and augment the text. Each figure should be submitted on a separate page. Legends should be typed in 12-point font, double-spaced, and located after the references with the titles in clauses. Figures in PDF are not acceptable. Photographs must be submitted electronically according to the following specifications: color photographs should be saved as TIF files in RGB at a minimum of 12.5 cm (5 in.) in width at 300 dpi; black and white photographs should be saved as TIF files in grayscale at a minimum of 12.5 cm (5 in.) in width at 300 dpi. Authors should note that all photographs with discriminability of the patients’ identity (not limited to the face) must be submitted with the publication of patient information form and the authors take the legal responsibility in case of lawsuits. Symbols, arrows or letters used to identify parts of the figures must be explained clearly in the legend. The illustrations of pathological tissue should state clearly the type of stain and the magnifying power (e.g., H&E, ×400), and the main contents should be marked by signs or arrows on the picture. Line drawings should be original copies. A previously published figure should be accompanied by the footnote acknowledging the original source and the consent of copyright holder.